Evotec and APEIRON Biologics start next project on the Cbl-b target
Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.
Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enhance anti-tumor activities both for tumor antigen-specific cells and for those recognizing general features of tumor cells.
Evotec will apply their skills and proprietary technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b. The aim of the collaboration will be to take compounds identified by Evotec as being active against this target or other relevant targets and further jointly optimize them as basis for formal preclinical and clinical development.
No financial details are disclosed.
Other news from the department business & finance
Most read news
Last viewed contents
Government programs play huge role in growth of healthcare market in turkey, finds Frost & Sullivan - Merger and acquisition activities will increase as economy improves
Unusual protein modification involved in muscular dystrophy, cancer
Virtual human in HIV drug simulation
Off the shelf, on the skin - Stick-on electronic patches for health monitoring
Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Celera and Collaborators Discover a Genetic Marker Associated with Severe Coronary Artery Disease - Carriers of gene variant exhibit an approximate 3-fold increased risk of disease
Cells talk at each other to specialize different functions - New concept to describe how cells specialize during development
The French biotechnology industry on the launchpad - France Biotech recommends accelerating efforts to allow takeoff - France Biotech unveils « 2004 French Biotechnology Industry Report » on December 15th in Paris
